Strong Financial Performance
BWXT reported 14% organic revenue growth, 19% adjusted EBITDA growth, and 24% adjusted earnings per share growth for Q3 2024.
Raised 2024 Guidance
The company raised its 2024 adjusted earnings per share guidance to about $3.20 and maintained its free cash flow guidance of $225 million to $250 million.
Acquisition of A.O.T.
Announced the acquisition of A.O.T., expected to close by year-end, adding $40 million in 2024 sales and mid-teens EBITDA margins to the portfolio.
Government Operations Growth
Government Operations segment saw 17% revenue growth and 18% adjusted EBITDA growth, led by naval propulsion and Technical Services.
Commercial Operations Growth
Modest revenue growth driven by robust medical and commercial nuclear components growth.
BWXT Medical Performance
BWXT Medical experienced year-to-date growth in line with full-year expectations of about 25%.